NCT05851456View on ClinicalTrials.gov

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 10, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
OsteosarcomaSarcomaSarcoma,Soft TissueBone Tumor
Interventions
DRUG

Recombinant oncolytic herpes simplex virus type Ⅰ (R130)

R130, a modified herpes simplex virus-Ⅰ (HSV-1) containing the gene coding for anti-CD3 scFv/CD86/PD1/HSV2-US11

Trial Locations (1)

710000

RECRUITING

Xi'an Honghui Hospital, Xi'an

All Listed Sponsors
collaborator

Xi'an Honghui Hospital

OTHER

lead

Shanghai Yunying Medical Technology

INDUSTRY